BRAF and metastatic melanoma: Approximately 50% of patients with metastatic melanoma harbor mutations for the serine/threonine-protein kinase BRAF resulting in constitutive activation of the mitogen activated protein kinase cascade; a significant proportion of these melanomas are intrinsically resistant to BRAF inhibitors while others acquire resistance within a few months (Welsh et al., 2016).